Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

被引：0
|
作者：
N. I. Bouwer
T. G. Steenbruggen
J. van Rosmalen
H. N. Rier
J. J. E. M. Kitzen
M. L. van Bekkum
A. J. Ten Tije
P. C. de Jong
J. C. Drooger
C. Holterhues
C. H. Smorenburg
M. J. M. Kofflard
E. Boersma
G. S. Sonke
M.-D. Levin
A. Jager
机构：
[1] Albert Schweitzer Hospital,Department of Internal Medicine
[2] Albert Schweitzer Hospital,Department of Cardiology
[3] The Netherlands Cancer Institute,Department of Medical Oncology
[4] Erasmus MC,Department of Biostatistics
[5] University Medical Centre Rotterdam,Department of Medical Oncology
[6] Erasmus MC,Department of Medical Oncology
[7] Cancer Institute,Department of Medical Oncology
[8] Reinier de Graaf Hospital,Department of Medical Oncology
[9] Amphia Hospital,Department of Medical Oncology
[10] Sint Antonius Hospital,Department of Medical Oncology
[11] Ikazia Hospital,Department of Cardiology
[12] Haga Hospital,undefined
[13] Erasmus MC,undefined
[14] University Medical Centre Rotterdam,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 186卷
关键词：
HER2-positive metastatic breast cancer; Trastuzumab treatment; Cardiotoxicity; LVEF monitoring; Screening for cardiotoxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：851 / 862
页数：11
相关论文
共 50 条
  • [1] Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
    Bouwer, N., I
    Steenbruggen, T. G.
    van Rosmalen, J.
    Rier, H. N.
    Kitzen, J. J. E. M.
    van Bekkum, M. L.
    Ten Tije, A. J.
    de Jong, P. C.
    Drooger, J. C.
    Holterhues, C.
    Smorenburg, C. H.
    Kofflard, M. J. M.
    Boersma, E.
    Sonke, G. S.
    Levin, M-D
    Jager, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 851 - 862
  • [2] Long-term responders to trastuzumab among patients with HER2-positive metastatic breast cancer
    Barriere, J.
    Mari, V.
    Follana, P.
    Largillier, R.
    Chamorey, E.
    Lescaut, W.
    Flipo, B.
    Ettore, F.
    Raoust, I.
    Peyrottes, I.
    Figl, A.
    Marcy, M.
    Ihrai, T.
    Courdi, A.
    Ferrero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Long-term continuous Trastuzumab use for HER2-positive advanced breast cancer
    Shukur, Haider Y.
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2020, 6 (05): : 234 - 241
  • [4] Optimal Duration of Cardiac Monitoring in Metastatic HER2-positive Breast Cancer Patients Receiving Trastuzumab
    Chiu, K.
    Dubey, S.
    Bull, D.
    CLINICAL ONCOLOGY, 2014, 26 : S3 - S3
  • [5] LACK OF CARDIAC EVENTS DURING TRASTUZUMAB AND PERTUZUMAB THERAPY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER: IMPLICATIONS FOR CARDIAC MONITORING
    Yu, Anthony F.
    Manrique, Carlos
    Liu, Jennifer
    Hudis, Clifford A.
    Steingart, Richard
    Dang, Chau
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1330 - A1330
  • [6] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [7] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Volkmar Müller
    Michael Clemens
    Jacek Jassem
    Nedal Al-Sakaff
    Petra Auclair
    Eveline Nüesch
    Debbie Holloway
    Mona Shing
    Yung-Jue Bang
    BMC Cancer, 18
  • [8] Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
    Izzet Dogan
    Esra Aydin
    Nijat Khanmammadov
    Nail Paksoy
    Pinar Saip
    Adnan Aydiner
    Scientific Reports, 13
  • [9] Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
    Dogan, Izzet
    Aydin, Esra
    Khanmammadov, Nijat
    Paksoy, Nail
    Saip, Pinar
    Aydiner, Adnan
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [10] Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    Park, Ji Soo
    Youn, Jong-Chan
    Shim, Chi Young
    Hong, Geu-Ru
    Lee, Choong-Kun
    Kim, Jee Hyung
    Park, Hyung Soon
    Heo, Su Jin
    Beom, Seung Hoon
    Kim, Hyo Song
    Rha, Sun Young
    Chung, Hyun Cheol
    Kang, Seok-Min
    Jung, Minkyu
    ONCOTARGET, 2017, 8 (37) : 61837 - 61845
12345